17,261 trials
Colorectal Cancer
Primary: Percentage of Participants Achieving Overall Disease Control (ODC) — 87 percentage of participants
Cervical Cancer
Primary: Anti-tumor Activity as Measured by Surviving Progression-free — 59 percentage of participants
Neisseria Meningitidis · Haemophilus Influenzae Type b
Primary: Number of Seroprotected Subjects for Anti-polyribosylribitol Phosphate (Anti-PRP). — 108; 111 Participants
Chronic Periodontitis
Primary: Change in Periodontal Inflammation Surface Area (PISA) — 638.16; 288.72 square millimeters
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
Renal Transplantation
Primary: Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84 — 8.4; 11.1; 9.7 Weeks * Percentage of saturated CD25
Trichotillomania · Hair Pulling
Primary: Massachusetts General Hospital Hair Pulling Scale (MGH-HPS) — 10.70; 13.53 units on a scale
Acne
Primary: Percent Change in Inflammatory Acne Lesion Counts — -28.6; -44.3; -44.4 Percentage change from baseline — p=0.1919
Hereditary Angioedema (HAE)
Primary: Presence of Unequivocal Beginning of Relief of the Defining Attack Symptom — 3; 3; 3; 0 participants
Lymphoma
Primary: Number of Participants With Overall Response — 25; 27 participants
Caries
Primary: Percentage (%) Change in Surface Microhardness (SMH) Following 21 Days of Twice Daily Treatment With the 1500 Ppm Fluoride + 5% CSP Dentifrice and With the 1500 Ppm…
Type 2 Diabetes Mellitus · Secondary Hypogonadism
Primary: Change in HbA1C — 0; 0; 0 Ratio
Spinal Cord Injuries
Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale
Multiple Myeloma
Primary: Clinical Response to Treatment — 81.5 percentage of participants
Advanced Cancer
Primary: Herth Hope Index — 37.79; 39.74; 39.06; 38.17 units on a scale — p=<0.05